Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before selecting or changing a continuous glucose monitoring system.

CGM Devices Compared: Dexcom, Libre, and Medtronic

Last updated: March 2026 | Reviewed by MDTalks Editorial Team

Continuous glucose monitoring (CGM) has fundamentally changed how people with diabetes track and manage blood sugar. Rather than relying on periodic fingerstick checks, CGM systems provide a near-continuous stream of glucose data, revealing trends, patterns, and alerts that fingersticks cannot capture. The 2026 ADA Standards of Care now recommend CGM consideration for individuals with type 2 diabetes on basal insulin, broadening previous guidance that focused on type 1 and intensive insulin therapy.

Three manufacturers dominate the CGM market: Dexcom, Abbott (FreeStyle Libre), and Medtronic. Here is how their current-generation devices compare.

---

Head-to-Head Comparison

Feature	Dexcom G7	FreeStyle Libre 3	Medtronic Simplera
Sensor duration	10 days (+12h grace)	14 days	7 days
Warm-up time	30 minutes	60 minutes	120 minutes
Accuracy (MARD)	8.2%–9.1%	8.9%–9.7%	Higher variability in studies
Real-time readings	Automatic every 5 min	Automatic every 1 min	Automatic every 5 min
Alerts/alarms	Customizable high/low, urgent low, predictive	Customizable high/low, urgent low	Customizable, integrates with pump
Calibration	Factory calibrated (no fingersticks)	Factory calibrated	Factory calibrated
Sensor size	Smaller than G6	Smallest current sensor	Compact, all-in-one
Smartphone compatibility	iOS, Android	iOS, Android	Guardian app (limited)
Pump integration	Tandem t:slim X2, Omnipod 5	Limited (Omnipod 5 under development)	MiniMed 780G
Approximate monthly cost	$300–$400 (without insurance)	$150–$250 (without insurance)	$300–$400 (without insurance)
Medicare/insurance coverage	Yes (therapeutic CGM)	Yes (therapeutic CGM)	Yes (with qualifying pump)

Note: Costs are approximate retail prices as of early 2026 and vary significantly based on insurance, pharmacy benefits, and manufacturer discount programs. Consult your insurer for specific coverage details.

---

Accuracy: What the Studies Show

Mean Absolute Relative Difference (MARD) is the standard measure of CGM accuracy. Lower MARD means closer alignment with laboratory glucose values. A MARD below 10% is generally considered clinically accurate.

A 2025 head-to-head study in adults with type 1 diabetes found:

• FreeStyle Libre 3: Overall MARD of 8.9%, with particularly strong performance after the first 12 hours
• Dexcom G7: Overall MARD of 13.6% in this study, though other studies have reported 8.2% to 9.1%
• Medtronic Simplera: Showed lower glucose readings on average compared to the other two systems

It is worth noting that accuracy can vary based on individual physiology, sensor placement, and hydration status. A single study does not capture the full picture; both Dexcom G7 and Libre 3 have extensive supporting evidence of clinical accuracy.

---

Choosing the Right CGM

The best CGM depends on your specific situation:

Choose Dexcom G7 if:

• You use an insulin pump (Tandem t:slim X2 or Omnipod 5) and want integrated automated insulin delivery
• Predictive alerts for impending lows are a priority
• You have type 1 diabetes and need real-time data with minimal lag

Choose FreeStyle Libre 3 if:

• Cost is a primary concern (generally the most affordable option)
• You prefer longer sensor wear (14 days vs. 10)
• You want the smallest sensor profile
• You have type 2 diabetes and are looking for an entry-level CGM

Choose Medtronic Simplera if:

• You already use a Medtronic MiniMed 780G insulin pump
• You want a fully integrated pump-CGM system from a single manufacturer

For context on how CGM fits into overall monitoring strategy, see Blood Sugar Monitoring: How Often and When to Test.

---

Key CGM Metrics to Track

Beyond raw glucose numbers, CGM data provides several metrics that help guide diabetes management:

• Time in Range (TIR): Percentage of time glucose stays between 70 and 180 mg/dL. Target: 70% or higher for most adults.
• Time Below Range (TBR): Percentage below 70 mg/dL. Target: less than 4%.
• Time Above Range (TAR): Percentage above 180 mg/dL. Target: less than 25%.
• Glucose Management Indicator (GMI): An estimate of A1C based on CGM data.
• Coefficient of Variation (CV): Measures glucose variability. Target: below 36%.

Understanding these metrics and sharing your CGM reports with your endocrinologist or diabetes care team enables more data-driven treatment decisions.

Learn what A1C means and how it relates to CGM data in What Is A1C? Understanding Your Average Blood Sugar.

---

Insurance and Cost Considerations

Most major insurance plans and Medicare cover CGM for people with diabetes who use insulin. Coverage criteria typically include:

• A diagnosis of type 1 or type 2 diabetes
• Use of insulin (for Medicare: three or more daily injections or an insulin pump)
• Willingness to use the CGM data to adjust therapy
• Prescription from a healthcare provider

The 2026 ADA Standards of Care expansion to recommend CGM for type 2 diabetes patients on basal insulin may lead to broader insurance coverage. Check with your specific plan and ask your diabetes care team about manufacturer assistance programs if cost is a barrier.

For the complete picture of diabetes management, see the Complete Guide to Diabetes Management in 2026.

---

Key Takeaways

• All three major CGM systems (Dexcom G7, FreeStyle Libre 3, Medtronic Simplera) offer factory-calibrated, real-time glucose monitoring with customizable alerts.
• Libre 3 offers the longest wear time (14 days) and generally lowest cost; Dexcom G7 offers the broadest pump integration; Medtronic Simplera integrates exclusively with Medtronic pumps.
• Accuracy is clinically acceptable across all three systems, with MARD values generally below 10%.
• The 2026 ADA Standards now recommend CGM consideration for type 2 diabetes patients on basal insulin.
• The right CGM depends on your insulin delivery method, budget, pump compatibility, and personal preferences.
• Consult your healthcare provider and diabetes educator to select the CGM that best fits your treatment plan and lifestyle.

---

Sources

1. American Diabetes Association. “7. Diabetes Technology: Standards of Care in Diabetes — 2026.” Diabetes Care, January 2026. pmc.ncbi.nlm.nih.gov
2. Wadwa RP, et al. “Performance of Three Continuous Glucose Monitoring Systems in Adults With Type 1 Diabetes.” Diabetes Technology & Therapeutics, 2025. pmc.ncbi.nlm.nih.gov
3. National Institute of Diabetes and Digestive and Kidney Diseases. “Continuous Glucose Monitoring.” niddk.nih.gov

---

This article is part of the MDTalks Diabetes Hub. For AI health comparisons, see AI Answers About Diabetes.

Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before selecting or changing diabetes technology.